Abivax

ABVX

Market cap $7.22B

ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials, targeting a large, fast-growing inflammatory bowel disease market. Upcoming Phase 3 maintenance data in Q2 2026 is a major catalyst, with positive results likely to unlock significant upside for ABVX shares.

ABIVAX Société Anonyme (NASDAQ:ABVX ) Shareholder/Analyst Call October 6, 2025 9:00 AM EDT Company Participants Patrick Malloy - Senior Vice President of Investor Relations Marc M. de Garidel - CEO & Director Chris Rabbat - VP & Global Head of Medical Affairs Fabio Cataldi - Chief Medical Officer Conference Call Participants Marla C.

Abivax SA (NASDAQ:ABVX) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting.

Leading biotech stock Abivax jumped Monday on compelling test results for its experimental ulcerative colitis treatment.

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices.

Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30, 2025.

Results of a Paris company's late-stage drug trial helped turn things around for healthcare-focused funds, which struggled in the first half of the year.